Back

Andrew Blauvelt, MD, MBA, and Joseph F. Merola, MD, MMSc, review data showing IL-17 and IL-23 inhibitors do not raise TB risk and when testing still fits.

TB Testing and IL-17, IL-23 Inhibitors in Psoriasis: A New Joint Statement

Episodes

Specialty:

All

Year:

All

EP. 1: Why Psoriasis Experts Are Rethinking TB Testing for IL-17, IL-23 Inhibitors

ByAndrew Blauvelt, MD ,Joseph Merola, MD, MMSc

October 20th 2026

New NPF/IPC guidance questions routine TB testing for IL-17 and IL-23 inhibitors in psoriasis, a TNF-era practice lacking direct supporting evidence.

EP. 2: 4 Lines of Evidence Behind Dropping TB Testing for IL-17, IL-23 Inhibitors

ByAndrew Blauvelt, MD ,Joseph Merola, MD, MMSc

October 20th 2026

Basic science, trials, real-world data, and FAERS reports show little TB reactivation risk with IL-17 and IL-23 inhibitors, supporting new NPF/IPC guidance.

EP. 3: Why the TB Testing Statement Stops Short of Ustekinumab and TYK2 Inhibitors

ByAndrew Blauvelt, MD ,Joseph Merola, MD, MMSc

October 20th 2026

Experts explain why ustekinumab and TYK2 inhibitors were excluded from new TB testing guidance and how FDA label changes for IL-17/IL-23 agents could happen.

EP. 4: TB Testing in Endemic Regions, Combination Therapy, and Broader DMARDs

ByAndrew Blauvelt, MD ,Joseph Merola, MD, MMSc

October 20th 2026

The NPF/IPC TB statement isn’t a blanket no-test rule. Experts explain when screening still fits, from endemic regions to JAK inhibitors and other DMARDs.

EP. 5: The Hidden Costs of Routine TB Testing Before IL-17 and IL-23 Inhibitors

ByAndrew Blauvelt, MD ,Joseph Merola, MD, MMSc

October 20th 2026

From false positives to lost follow-up and unneeded LTBI therapy, experts detail the harms of routine TB testing with IL-17 and IL-23 inhibitors in psoriasis.